Highlights Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 08:05:18 2026-04-16 am EDT			5-day change	1st Jan Change
76.10 ^GBX	+2.84%		+7.80%	+31.97%

Apr. 09	Somero Enterprises extends buyback to USD6.0 million	AN
Apr. 09	Avacta hails "important milestones" in start of "transformative" year	AN

Highlights

Apr. 09	Somero Enterprises extends buyback to USD6.0 million	AN
Apr. 09	Avacta hails "important milestones" in start of "transformative" year	AN
Mar. 31	Avacta Therapeutics Announces First Patient Treated In Phase 1 Focus-01 Trial Of FAP-Exd	CI
Mar. 16	Avacta Group announces phase 1 study opening for AVA6103	RE
Feb. 24	Avacta hails new data supporting proprietary preCision platform	AN
Feb. 24	Avacta's pre\|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis	CI
Feb. 03	Avacta Therapeutics Announces Two Key Clinical Updates to its Faridoxorubicin Clinical Program	CI
Jan. 21	Avacta Therapeutics Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug Application for the Second Pre\|Cision® Medicine, Fap-Exatecan	CI
Jan. 21	EARNINGS AND TRADING: Kenmare meets guidance, plans to lower costs	AN
Jan. 21	Avacta announces US FDA clearance of the investigational new drug application for the second pre\|CISION medicine, FAP-Exatecan	RE
Jan. 21	Avacta Therapeutics Wins US FDA Nod to Start Early-stage Trial of Cancer Drug FAP-Exd	MT
Jan. 20	EARNINGS AND TRADING: Treatt cuts dividend after "challenging year"	AN
Dec. 18	Avacta Reports New Pharmacology Data for Fap-Exd	CI
Dec. 17	Avacta Therapeutics Announces Faridoxorubicin Phase 1B Cohort Demonstrates Clinically Meaningful Tumor Shailage in Patients with Salivary Metals Cancer	CI
25-10-25	Avacta Presents First Preclinical Data from Dual Payload Pre\|Cision® Medicines At the 2025 Aacr-Nci-Eortc International Conference on Molecular Targets	CI
25-10-19	Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre\|CISION®? Platform at the European Society of Medical Oncology Annual Congress	CI
25-09-30	Avacta Group Plc Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-09-30	EARNINGS: Suspension damages Enwell Energy; forex hurts Hemogenyx	AN
25-09-30	Earnings Flash (AVCT.L) Avacta Group Reports H1 Revenue GBP56,000	MT
25-09-01	Avacta completes GBP2 million Coris Bioconcept sale	AN
25-09-01	Avacta Group Concludes Sale of Rapid Diagnostic Tests Business	MT
25-08-28	Trupcr Europe Limited and 3B Blackbio Dx Limited completed the acquisition of CorisBioConcept SPRL from Avacta Group Plc.	CI
25-07-30	Avacta Therapeutics to Present New FAP Dox Data at the European Society for Medical Oncology Congress	CI
25-07-28	Trupcr Europe Limited and 3B Blackbio Dx Limited entered into a definitive agreement to acquire CorisBioConcept SPRL from Avacta Group Plc for £2.8 million.	CI
25-07-28	Avacta Group sells Coris to transition to therapeutics business	AN